Study of lurbinectedin efficacy and safety in participants with advanced or metastatic solid tumors
Enrolling By Invitation
18 years - 99 years
All
Phase
2
60 participants needed
1 Location
Brief description of study
This research study is designed to learn more about the safety and effectiveness of lurbinectedin given to individuals who have been diagnosed with advanced (metastatic and/or unresectable) solid tumors.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: metastatic solid tumors
-
Age: 18 years - 99 years
-
Gender: All
Male or Female; Age 18 or older, metastatic solid tumors
Updated on
04 Aug 2024.
Study ID: 850285
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
